Currently out of the existing stock ratings of Keyur Parekh, 6 are a BUY (75%), 2 are a HOLD (25%).

Keyur Parekh

Work Performance Price Targets & Ratings Chart

Analyst Keyur Parekh, carries an average stock price target met ratio of 50% that have a potential upside of 30.6% achieved within 627 days.

Keyur Parekh’s has documented 15 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 24-Feb-2023.

Wall Street Analyst Keyur Parekh

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 1/26/2022. The price target of $60.58 was fulfilled within 316 days with a profit of $17 (39.01%) receiving and performance score of 1.23.

Average potential price target upside

AZN AstraZeneca PLC ADR NVS Novartis AG ADR SNY Sanofi ADR NVO Novo Nordisk A/S GSK GlaxoSmithKline PLC ADR

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

Since 03-Jul-2023

2 months 26 days ago
(16-Oct-2025)

1/11 (9.09%)

$83.68 (135.40%)

2598

Buy

Since 27-Jan-2020

$87

$-7.65 (-8.08%)

$78

1 years 1 months 24 days ago
(18-Nov-2024)

9/9 (100%)

$24.91 (40.12%)

608

Buy

Since 05-Jan-2023

$88

$-6.65 (-7.03%)

$82

1 years 1 months 29 days ago
(13-Nov-2024)

5/5 (100%)

$24.05 (37.61%)

325

Buy

Since 01-Apr-2019

$95

$0.35 (0.37%)

$66

1 years 4 months 30 days ago
(12-Aug-2024)

7/7 (100%)

$14.17 (17.53%)

503

Buy

Since 29-Aug-2022

$85

$-9.65 (-10.20%)

$80

1 years 7 months 12 days ago
(30-May-2024)

4/4 (100%)

$10.26 (13.73%)

414

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Keyur Parekh?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?